Krishna R. Patel PharmD RPh's blog
Krishna R. Patel, PharmD, RPh
If you haven’t already heard about the negative impact of formulary restrictions on adherence, well here it is. With mixed messages regarding formulary restrictions’ impact on patients, a recently published systematic literature review, published by Happe, et al., sought to get to the bottom this.
Krishna R. Patel, PharmD, RPh
Apps will begin to be prescribed by physicians by the end of this year. Call it disruption, innovation, or crossroad, but it will be here and the question is are we ready for it?
WellDoc has been selling type 2 diabetes apps, and will now be the first to launch a prescription app. Go ahead and search for “mobile diabetes management” on clinicaltrials.gov and what you find may surprise you. Just like drugs that must be approved by the FDA after presenting landmark clinical trials, BlueStar is a prescription app for Type 2 diabetes that was approved by the FDA upon showing efficacy and safety data.
Ford Motor Co. and Rite Aid are already catching on, as they have agreed to reimburse employees for using BlueStar through their prescription benefit plans. BlueStar manages patients’ disease by not only monitoring but also providing feedback to them and to their doctors.
Just as with any other drug, the health care provider prescribes the app for one month, along with refills. The prescription is received by the pharmacy, which runs it through the insurance company and also forwards the claim to WellDoc. A WellDoc trainer approaches the patient to set up the app on the patient’s mobile phone or laptop and also to provide instructions.
Krishna R. Patel, PharmD, RPh
Research from the New England Healthcare Institute has the world rethinking what the next great advance in health care will look like. While many of us are only now beginning to hear the noise about medication nonadherence, health care leaders are already hot on the trail to finding effective ways to reduce nonadherence.
Meetings
PCMH & Shared Savings ACO Leadership Summit |
Nashville, TN |
November 3–4, 2014 |
2014 Annual HEDIS® and Star Ratings Symposium |
Nashville, TN |
November 3–4, 2014 |
Medicare Risk Adjustment, Revenue Management, & Star Ratings |
Fort Lauderdale, FL |
November 12–14, 2014 |
World Orphan Drug Congress Europe 2014 |
Brussels, Belgium |
November 12–14, 2014 |
Healthcare Chief Medical Officer Forum |
Alexandria, VA |
November 13–14, 2014 |
Home Care Leadership Summit |
Atlanta, GA |
November 17–18, 2014 |
HealthIMPACT Southeast |
Tampa, FL |
January 23, 2015 |
Our other journal
P&T Journal for September 2014
Features
Health Care & Law
Legal Risk Management Opportunities, Pharmacy Practice, and P&T Committees
Hospitals Struggle With ACA Challenges
Drug–Gene Interactions: Inherent Variability in Drug Maintenance Dose Requirements
Schizophrenia: Overview and Treatment Options
Pipeline Plus
Schizophrenia Therapy Options Increasing
Departments
Medication Errors
Too Many Abandon the “Second Victims” of Medical Errors
Prescription: Washington
New Controversy for 340B: OPA Rebuffs Ruling by Court
New Drugs/Drug News/New Medical Devices
Pharmaceutical Approval Update
Drug Forecast
Loxapine Inhalation Powder (Adasuve)